| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8211438 | International Journal of Radiation Oncology*Biology*Physics | 2018 | 7 Pages |
Abstract
Patients who received no salvage treatment had poorer survival than those who received radiation, chemotherapy, or the combination. However, patient selection for no treatment likely reflects poorer expected prognosis. There was no significant survival difference among those receiving radiation therapy, systemic therapy, or both. Ongoing clinical trials will help define the role of reirradiation after glioblastoma progression.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Wenyin MD, PhD, Molly PhD, Mark R. MD, Minesh P. MD, Deborah T. MD, Paul D. MD, Egils MD, Kirsten MD, Luis MD, David W. MD, Tzahala MD, Steve P. MD, PhD, Emad F. MD, Nathalie MD, James J. PhD, Maria MD,